Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease

A potential approach to identify atherosclerotic disease progression

Paul A. Gurbel, Rolf Kreutz, Kevin P. Bliden, Joseph DiChiara, Udaya S. Tantry

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: The study rationale was to compare the biomarker profile of metalloproteinases (MMPs) and inflammation markers (IMs) in patients requiring revascularization with that of patients with long-term, clinically quiescent coronary artery disease (CAD). Methods: Seventy-eight patients with symptomatic CAD (S-CAD) (7 patients with myocardial infarction and 71 patients with stable angina) and 67 patients with asymptomatic CAD (A-CAD) were enrolled. Plasma samples were analyzed for MMPs, MMP inhibitors (MMPIs), IMs, coagulation factors, and apolipoproteins by use of the fluorokine multianalyte profiling assay. Results: Patients with S-CAD had markedly elevated levels of specific MMPs (MMP-2, MMP-9), MMPIs (α2-macroglobulin, tissue inhibitor of MMP 1), IMs (C-reactive protein; interleukin [IL] 8; IL-10, regulated upon activation, normal T-cell expressed and secreted [RANTES], endothelin, plasminogen activator inhibitor 1, and apolipoprotein C-III compared with patients with A-CAD (P <.005 for all measurements), whereas patients with A-CAD had significantly greater levels of MMP-3 and IL-1α compared with patients with S-CAD (P ≤ .02 for both measurements). Conclusions: A specific profile of MMPs, IMs, and other biomarkers distinguishes the patient with progressive coronary atherosclerosis culminating in either elective or emergent percutaneous coronary intervention from the patient with quiescent disease. The early implementation of a biomarker analysis may identify the patient at risk for plaque progression and refine the definition of "stable" angina.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
JournalAmerican Heart Journal
Volume155
Issue number1
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Disease Progression
Coronary Artery Disease
Biomarkers
Matrix Metalloproteinases
Matrix Metalloproteinase Inhibitors
Inflammation
Stable Angina
Apolipoprotein C-III
Macroglobulins
Blood Coagulation Factors
Apolipoproteins
Plasminogen Activator Inhibitor 1
Endothelins
Metalloproteases
Percutaneous Coronary Intervention
Interleukin-8
Interleukin-1
Interleukin-10
C-Reactive Protein
Myocardial Infarction

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{ef63afa9fd884b89992b311325eb3037,
title = "Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: A potential approach to identify atherosclerotic disease progression",
abstract = "Background: The study rationale was to compare the biomarker profile of metalloproteinases (MMPs) and inflammation markers (IMs) in patients requiring revascularization with that of patients with long-term, clinically quiescent coronary artery disease (CAD). Methods: Seventy-eight patients with symptomatic CAD (S-CAD) (7 patients with myocardial infarction and 71 patients with stable angina) and 67 patients with asymptomatic CAD (A-CAD) were enrolled. Plasma samples were analyzed for MMPs, MMP inhibitors (MMPIs), IMs, coagulation factors, and apolipoproteins by use of the fluorokine multianalyte profiling assay. Results: Patients with S-CAD had markedly elevated levels of specific MMPs (MMP-2, MMP-9), MMPIs (α2-macroglobulin, tissue inhibitor of MMP 1), IMs (C-reactive protein; interleukin [IL] 8; IL-10, regulated upon activation, normal T-cell expressed and secreted [RANTES], endothelin, plasminogen activator inhibitor 1, and apolipoprotein C-III compared with patients with A-CAD (P <.005 for all measurements), whereas patients with A-CAD had significantly greater levels of MMP-3 and IL-1α compared with patients with S-CAD (P ≤ .02 for both measurements). Conclusions: A specific profile of MMPs, IMs, and other biomarkers distinguishes the patient with progressive coronary atherosclerosis culminating in either elective or emergent percutaneous coronary intervention from the patient with quiescent disease. The early implementation of a biomarker analysis may identify the patient at risk for plaque progression and refine the definition of {"}stable{"} angina.",
author = "Gurbel, {Paul A.} and Rolf Kreutz and Bliden, {Kevin P.} and Joseph DiChiara and Tantry, {Udaya S.}",
year = "2008",
month = "1",
doi = "10.1016/j.ahj.2007.08.021",
language = "English (US)",
volume = "155",
pages = "56--61",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease

T2 - A potential approach to identify atherosclerotic disease progression

AU - Gurbel, Paul A.

AU - Kreutz, Rolf

AU - Bliden, Kevin P.

AU - DiChiara, Joseph

AU - Tantry, Udaya S.

PY - 2008/1

Y1 - 2008/1

N2 - Background: The study rationale was to compare the biomarker profile of metalloproteinases (MMPs) and inflammation markers (IMs) in patients requiring revascularization with that of patients with long-term, clinically quiescent coronary artery disease (CAD). Methods: Seventy-eight patients with symptomatic CAD (S-CAD) (7 patients with myocardial infarction and 71 patients with stable angina) and 67 patients with asymptomatic CAD (A-CAD) were enrolled. Plasma samples were analyzed for MMPs, MMP inhibitors (MMPIs), IMs, coagulation factors, and apolipoproteins by use of the fluorokine multianalyte profiling assay. Results: Patients with S-CAD had markedly elevated levels of specific MMPs (MMP-2, MMP-9), MMPIs (α2-macroglobulin, tissue inhibitor of MMP 1), IMs (C-reactive protein; interleukin [IL] 8; IL-10, regulated upon activation, normal T-cell expressed and secreted [RANTES], endothelin, plasminogen activator inhibitor 1, and apolipoprotein C-III compared with patients with A-CAD (P <.005 for all measurements), whereas patients with A-CAD had significantly greater levels of MMP-3 and IL-1α compared with patients with S-CAD (P ≤ .02 for both measurements). Conclusions: A specific profile of MMPs, IMs, and other biomarkers distinguishes the patient with progressive coronary atherosclerosis culminating in either elective or emergent percutaneous coronary intervention from the patient with quiescent disease. The early implementation of a biomarker analysis may identify the patient at risk for plaque progression and refine the definition of "stable" angina.

AB - Background: The study rationale was to compare the biomarker profile of metalloproteinases (MMPs) and inflammation markers (IMs) in patients requiring revascularization with that of patients with long-term, clinically quiescent coronary artery disease (CAD). Methods: Seventy-eight patients with symptomatic CAD (S-CAD) (7 patients with myocardial infarction and 71 patients with stable angina) and 67 patients with asymptomatic CAD (A-CAD) were enrolled. Plasma samples were analyzed for MMPs, MMP inhibitors (MMPIs), IMs, coagulation factors, and apolipoproteins by use of the fluorokine multianalyte profiling assay. Results: Patients with S-CAD had markedly elevated levels of specific MMPs (MMP-2, MMP-9), MMPIs (α2-macroglobulin, tissue inhibitor of MMP 1), IMs (C-reactive protein; interleukin [IL] 8; IL-10, regulated upon activation, normal T-cell expressed and secreted [RANTES], endothelin, plasminogen activator inhibitor 1, and apolipoprotein C-III compared with patients with A-CAD (P <.005 for all measurements), whereas patients with A-CAD had significantly greater levels of MMP-3 and IL-1α compared with patients with S-CAD (P ≤ .02 for both measurements). Conclusions: A specific profile of MMPs, IMs, and other biomarkers distinguishes the patient with progressive coronary atherosclerosis culminating in either elective or emergent percutaneous coronary intervention from the patient with quiescent disease. The early implementation of a biomarker analysis may identify the patient at risk for plaque progression and refine the definition of "stable" angina.

UR - http://www.scopus.com/inward/record.url?scp=36849065911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36849065911&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2007.08.021

DO - 10.1016/j.ahj.2007.08.021

M3 - Article

VL - 155

SP - 56

EP - 61

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 1

ER -